Home Wellness Insights

28Jul

Compounded GLP-1 Statistics 2026 | FDA Crackdown & What Changed

Compounded GLP-1 Statistics 2026: FDA Crackdown, Safety Data & What Changed | GoalBMI Wellness

📊 Statistics Report — Updated July 2026

Compounded GLP-1 Statistics 2026: The FDA Crackdown, Safety Data & What Changed

Compounded semaglutide and tirzepatide access has changed dramatically since the shortages ended. Here’s the current data on FDA enforcement, adverse event reports, secret-shopper findings, and what legal treatment options remain.

📅 Last Updated: July 2026 ⏱ 12 min read ✔ Physician Reviewed 📚 10 Cited Sources

30%

Approx. share of US GLP-1 supply that was compounded at 2024 peak

On Healthcare, May 2026

92%

Of secret-shopper clinics still selling compounded semaglutide, mid-2026

JAMA Health Forum, 2026

455+

FDA adverse event reports linked to compounded semaglutide

FDA / Pharmacy Times, 2026

50+

FDA warning letters issued to compounders and telehealth firms in 2025

On Healthcare, 2026

For nearly three years, compounded semaglutide and tirzepatide gave patients an affordable alternative to brand-name GLP-1s during a nationwide drug shortage. That era is ending. Between resolved shortages, an FDA proposal to permanently close the compounding pathway, and mounting safety concerns, 2026 has brought the most significant shift in GLP-1 access since these drugs launched. Here’s the data on what changed, why, and what legitimate options remain.

Section 01

How the Compounding Market Got So Large

Compounded GLP-1s existed for one specific legal reason: FDA-declared drug shortages. When brand-name manufacturers couldn’t meet demand, compounding pharmacies were legally permitted to produce copies using the same active ingredients.

~30%

Of the entire US GLP-1 supply was compounded at peak in 2024

$150–300

Typical monthly cost of compounded versions vs. $1,000+ branded

2022

Year demand-driven shortages began, opening the compounding pathway

The price gap explains the scale: Compounded semaglutide and tirzepatide were sold for roughly $150 to $300 per month, compared with branded list prices exceeding $1,000. That price difference — combined with genuine supply shortages and thin insurance coverage — created what one industry analysis called a “robust market” that at its peak supplied nearly a third of the country’s GLP-1 use. (Source: Pharmacy Times, 2026)

Section 02

When the Legal Pathway Actually Closed

The FDA resolved both underlying shortages in a specific sequence, each one narrowing the legal basis for compounding.

Compounded GLP-1 Legal Pathway Timeline, 2024–2026

Source: FDA shortage database; Pharmacy Times; Healio, 2026.

Dec 2024

FDA declares the tirzepatide shortage resolved

Feb 2025

FDA declares the semaglutide shortage resolved

May 22, 2025

Final legal cutoff date for compounded semaglutide distribution

🚪

April 2026 — The FDA Moves to Close the Door Permanently

On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the “503B Bulks List” — the list of active ingredients large-scale outsourcing facilities are legally permitted to compound from. The FDA’s stated reason: there is no clinical need for outsourcing facilities to compound these drugs from bulk API now that supply is stable. If finalized, this closes the last major legal pathway for large-scale compounding. (Source: Stanford Medicine, July 2026)

Section 03

The Secret-Shopper Study: Compounding Continued Anyway

Perhaps the most striking 2026 finding is that the legal ending of shortages didn’t end the compounding market — at least not immediately.

A published JAMA Health Forum study sent researchers as secret shoppers to 75 brick-and-mortar weight-loss clinics and medical spas across two states — Oklahoma and West Virginia — between August and October 2025, months after the FDA’s legal cutoff dates. The results: 92.0% still offered compounded semaglutide and 86.7% still offered compounded tirzepatide. (Source: Medscape, 2026)

92%

Of 75 shopped businesses still sold compounded semaglutide

86.7%

Still sold compounded tirzepatide

58.7%

Sold versions with unproven additives, most commonly vitamin B12

🧪

Additives and Salt Forms Add Another Layer of Risk

Many compounders differentiate their products with extra ingredients — most commonly vitamin B12, B6, niacinamide, glycine, or carnitine — that have no proven weight-loss benefit and are largely untested in combination. A 2026 study found that when tirzepatide is compounded with B12, the two substances can chemically bond into a new molecule not found in FDA-approved products. Some compounders also use chemically distinct “salt forms,” such as semaglutide sodium, which have not been proven safe and effective in humans. (Source: Stanford Medicine, 2026)

📋

Some Sellers Lacked Proper Licensing

The same study noted that some compounding facilities lacked licenses to perform sterile compounding or had recently faced disciplinary actions from state pharmacy boards — meaning the risk wasn’t limited to the drug formulation itself, but extended to the basic manufacturing conditions.

Section 04

What the Adverse Event Data Actually Shows

Regulatory concern isn’t theoretical. The FDA has been tracking adverse events tied specifically to compounded — not branded — GLP-1 products.

455+

FDA adverse event reports linked to compounded semaglutide, as of early 2025

320+

Reports associated with compounded tirzepatide over the same period

50+

FDA warning letters sent to compounders and telehealth distributors in 2025

Many of these reports involved dosing errors from patients self-administering incorrect amounts from multidose vials — a risk inherent to the compounded product format rather than the active ingredient itself. Some cases required hospitalization. (Source: FDA data via Pharmacy Times, 2026)

📬

A Single-Day Enforcement Surge in Early 2026

The FDA’s enforcement posture escalated sharply in 2026, including a reported 30 warning letters issued to telehealth companies in a single day as part of a broader crackdown on API supply chains and counterfeit product concerns entering the market through online channels. (Source: HealthFactsJournal, 2026)

Program Access

Legitimate Access at GoalBMI Wellness

Given the regulatory uncertainty and documented safety concerns around unregulated compounding, GoalBMI Wellness prioritizes FDA-approved brand-name medications when clinically appropriate, with insurance verification and transparent self-pay pricing — not unregulated multidose vials from unlicensed sources.

GoalBMI Wellness GLP-1 program pricing — FDA-approved medications with insurance and self-pay options

Verify Your Insurance View Program Pricing

Real Patient Outcomes

Before & After — Results From Physician-Supervised Programs

These results are from real GoalBMI Wellness patients using properly sourced, physician-supervised GLP-1 treatment — the safer alternative to the unregulated compounding risks outlined above.

Before and after semaglutide and tirzepatide weight loss results — GoalBMI Wellness physician-supervised patients

See more patient before & after results →

Results disclaimer: Individual results may vary. Photos represent real patients from physician-supervised GoalBMI Wellness programs shared with patient consent. Results depend on individual health factors, program adherence, and clinical evaluation.

Section 05

What Legal Options Remain for Patients

The end of mass compounding doesn’t mean patients are without affordable options — the landscape has simply shifted toward different legal pathways.

Option	Approx. Monthly Cost	Legal Status
Compounded GLP-1 (503B, bulk)	$150 – $300 (historical)	Closing — proposed permanent exclusion, April 2026
503A patient-specific compounding	Varies	Remains legal but cannot replicate 503B scale
TrumpRx negotiated brand pricing	~$245	Legal — announced Nov 2025
Manufacturer savings cards	As low as $25	Legal — eligible commercially insured patients
Wegovy DTC (direct)	~$1,349 list	Legal — brand-name, full price
Zepbound DTC, lower doses	~$1,086	Legal — brand-name, full price

⚖️

The FDA Has Explicitly Rejected Cost as a Justification

In its April 2026 proposal, the FDA explicitly rejected affordability and insurance access as constituting “clinical need” for continued bulk compounding. This is a significant legal position — it means price alone will not reopen the compounding pathway, regardless of how brand-name pricing evolves. (Source: On Healthcare, 2026)

What this means practically: Patients relying on compounded GLP-1s for affordability should treat this as a genuine access transition, not a temporary disruption. Reviewing insurance coverage, manufacturer savings programs, and negotiated pricing options like TrumpRx now — rather than waiting — is the more resilient approach.

Section 06

2022–2026 Compounded GLP-1 Regulatory Timeline

2022

Demand-Driven Shortages Begin

Explosive GLP-1 demand outpaces manufacturer supply, triggering FDA-declared shortages of both semaglutide and tirzepatide and opening the legal compounding pathway.

Peak 2024

Compounded Products Reach ~30% of US Supply

Compounded semaglutide and tirzepatide, priced at roughly $150–300/month versus $1,000+ branded, come to represent nearly a third of the entire US GLP-1 supply.

December 19, 2024

Tirzepatide Shortage Resolved

The FDA declares the tirzepatide shortage over, narrowing the legal basis for compounding this drug specifically.

February 21, 2025

Semaglutide Shortage Resolved

The FDA declares the semaglutide shortage resolved, closing the second major legal pathway. Grace periods for wind-down begin.

March–May 2025

Grace Periods End

The grace period for compounded tirzepatide ends in March 2025; the final legal cutoff for compounded semaglutide follows on May 22, 2025.

Aug–Oct 2025

Secret-Shopper Study Finds Continued Sales

Researchers document that 92% of 75 shopped businesses in two states still offered compounded semaglutide months after the legal cutoff, revealing significant enforcement gaps.

Early 2026

FDA Enforcement Escalates Sharply

The FDA issues a reported 30 warning letters to telehealth companies in a single day, part of a broader crackdown on API supply chains and counterfeit product concerns.

April 30, 2026

FDA Proposes Permanent 503B Exclusion

The FDA formally proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — the mechanism permitting large-scale outsourcing facility compounding — citing no remaining clinical need. If finalized, this closes the last major legal pathway for bulk compounding.

Section 07

Frequently Asked Questions

Mostly no, for large-scale (503B) compounding. The FDA resolved the drug shortages that legally permitted mass compounding — tirzepatide in December 2024 and semaglutide in February 2025 — with final cutoff dates in early-to-mid 2025. On April 30, 2026, the FDA proposed permanently excluding these drugs from the 503B Bulks List entirely. Limited 503A patient-specific compounding remains legal in narrower circumstances, but cannot replicate the scale of the earlier compounding market.

A secret-shopper study published in JAMA Health Forum found that 92% of 75 shopped businesses across two states still offered compounded semaglutide months after the legal cutoff dates, and 86.7% offered compounded tirzepatide. Researchers noted this reveals genuine enforcement challenges — some businesses lacked proper sterile compounding licenses or had recent disciplinary actions. The FDA has since escalated enforcement, including a reported 30 warning letters issued in a single day in early 2026.

Many compounders add ingredients like vitamin B12, B6, niacinamide, glycine, or carnitine — none of which have proven weight-loss benefit — to differentiate their product. A 2026 study found that when tirzepatide is compounded with B12 specifically, the two substances can chemically bond into an entirely new molecule that isn’t found in any FDA-approved product and hasn’t been tested for safety or effectiveness.

Several legal pathways exist: the TrumpRx negotiated pricing program caps brand-name costs at roughly $245/month; manufacturer savings cards can reduce costs to as little as $25/month for eligible commercially insured patients; and insurance verification may reveal coverage you weren’t aware of. The FDA has explicitly stated that cost alone does not justify reopening bulk compounding, so these legal channels are the more durable long-term options.

The FDA had logged over 455 adverse event reports linked to compounded semaglutide and over 320 for compounded tirzepatide as of early 2025, many involving dosing errors from multidose vials that required hospitalization. Additional risks include unproven salt forms like semaglutide sodium, untested additive combinations, and — per the 2025-2026 secret-shopper study — sourcing from facilities that sometimes lacked proper sterile compounding licenses.

References

Sources & References

1Healio (July 2026). Compounded Semaglutide, Tirzepatide Continued to Be Sold After Shortages Ended. healio.com
2Stanford Medicine (July 2026). Compounded GLP-1s: Why Doctors Worry and the FDA Is Cracking Down. med.stanford.edu
3Medscape (July 2026). Compounded GLP-1s Still Widespread Despite Shortage Fix. medscape.com
4HealthFactsJournal (May 2026). Compounded GLP-1 and the FDA Shortage List: 2026 Update. healthfactsjournal.com
5Pharmacy Times (July 2026). FDA Moves to Permanently Close the Door on Compounded GLP-1s. pharmacytimes.com
6On Healthcare (May 2026). FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide — Part II. onhealthcare.tech
7PeptidesExplorer (June 2026). Ozempic Statistics 2026: Market, Sales & Usage Data. peptidesexplorer.com
8AOL / Associated Press (2025). FDA Crackdown on Off-Brand Ozempic Products Set to Take Effect. aol.com
9Jastreboff A.M. et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 387(3), 205–216. doi.org/10.1056/NEJMoa2206038
10FDA (2026). Drug Shortages Database — Tirzepatide and Semaglutide. fda.gov

Medically Reviewed by Karla K. Mioduchoski, FNP-BC

Board-Certified Family Nurse Practitioner — GoalBMI Wellness

Karla K. Mioduchoski, FNP-BC is a board-certified Family Nurse Practitioner providing physician-supervised medical weight loss, GLP-1 support, and telehealth wellness care through GoalBMI Wellness. All regulatory and safety data in this article was reviewed for accuracy in July 2026.

Medical & Regulatory Disclaimer: This content is for informational and educational purposes only and does not constitute medical or legal advice. Regulatory status described here reflects publicly available FDA guidance and industry reporting as of July 2026 and is subject to change as rulemaking proceeds. Compounded medications, where legally available, are prepared by state-licensed 503A pharmacies based on individual prescriptions and are not FDA-approved. Always confirm current regulatory status with a licensed healthcare provider before starting or continuing any GLP-1 therapy. In a medical emergency, call 911.

Get Started

Book an appointment and take the first step toward better health.

Book Now

Related Weight Loss Programs